By Maxx Chatsko The psychedelic medicine pioneer is choosing to raise cash now before market conditions worsen. It’s been a rough 2022 for shareholders of MindMedicine (MNMD) . Unfortunately, if after-hours price movements hold, it’s about to get even worse. The Canadian drug developer announced its intention to conduct a public offering of common stock. The regulatory filing didn’t include the number of shares to be offered, but markets are likely to begin pricing in a healthy amount of upcoming dilution before the details emerge. The news adds to a tumultuous stretch. Shares have plunged nea…